Format

Send to

Choose Destination
Clin Chim Acta. 2019 Jan 22;491:81-84. doi: 10.1016/j.cca.2019.01.019. [Epub ahead of print]

Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?

Author information

1
Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain. Electronic address: alleo@santpau.es.
2
Centre for Memory Disturbances, Section of Neurology, Lab of Clinical Neurochemistry, University of Perugia, Perugia, Italy.
3
Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
4
Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Goettingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.

Abstract

Psychiatric disorders are currently classified, in the majority of cases, by clinical syndromes. However, advances over the last decade in imaging and biochemical biomarkers in several Central Nervous System (CNS) disorders anticipate the incorporation of some of these markers in the diagnostic work-up of psychiatric conditions. In particular, CSF biomarkers offer the possibility of detecting a wide range of pathophysiological processes in the CNS. Newer CSF markers can measure axonal and synaptic damage, glial activation, and oxidative stress in CNS disorders with high precision. The possibility that these markers can be applied in the differential diagnosis of common psychiatric disorders such as Schizophrenia, Major Depressive or Bipolar Disorders not only to rule out neurodegenerative diseases but also to identify specific biomarker signatures has yet to be explored. In particular, synaptic proteins in CSF could be useful as markers of synaptic and neurotransmitter transmission impairment since these are key molecular features of psychiatric conditions. In this paper we outline the current and potential applications of CSF biomarkers in psychiatric disorders.

KEYWORDS:

Alzheimer; Amyloid; CSF; Glia; Neurofilaments; Psychiatric disorders; Tau; YKL-40

PMID:
30682327
DOI:
10.1016/j.cca.2019.01.019

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center